Related Experiment Videos
Chylothorax in lymphangioleiomyomatosis
Jay H Ryu1, Clint H Doerr, Susan D Fisher
1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Chest
|February 11, 2003
Summary
Chylothorax in pulmonary lymphangioleiomyomatosis (LAM) has a variable course. Individualized treatment, from observation to pleurodesis with thoracic duct ligation, is recommended for managing this rare complication in women.
Area of Science:
- Pulmonology
- Rare Diseases
- Thoracic Surgery
Background:
- Pulmonary lymphangioleiomyomatosis (LAM) is a rare smooth muscle cell disorder affecting women of childbearing age.
- Chylothorax is a recognized complication of LAM, but its optimal management remains undefined.
Purpose of the Study:
- To characterize the clinical course of chylothorax in LAM patients.
- To identify effective management strategies for chylothorax in LAM.
Main Methods:
- Retrospective review of medical records of LAM patients with chylothorax.
- Analysis of clinical presentation, management, and outcomes.
Main Results:
- Chylothorax occurred in 10.1% of LAM patients (8/79).
- Management varied from thoracentesis to thoracic duct ligation and pleurodesis.
- Pleurodesis or parietal pleurectomy appeared effective for controlling chylothorax.
Conclusions:
- Chylothorax in LAM presents with a variable clinical course.
- Less invasive treatments may suffice, while pleurodesis with or without thoracic duct ligation is effective for intractable cases.
- Individualized management based on effusion characteristics and patient factors is crucial.